Yun H, Chen L, Xie F, et al. - Researchers explored different measurement tools that physicians applied to evaluate rheumatoid arthritis (RA) disease activity and associated RA treatment changes. Utilizing data from the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2016 and June 2017, and using the following criteria: age ≥ 18 years, diagnosis of RA (International Classification of Diseases, Ninth and Tenth Revision, codes), ≥ 2 RISE visits, and ≥ 1 RA disease activity measure scored in 2016, researchers assigned eligible patients’ drug use at the index visit as monotherapy or combination therapy with conventional synthetic (cs) and biologic disease-modifying antirheumatic drugs (bDMARDs). A total of 27,274 had longitudinal data among 50,996 eligible patients. The data showed that one- to two-thirds of RA individuals failed to change their treatment, despite when experiencing moderate/high disease activity using the American College of Rheumatology's national RISE registry. It was demonstrated that multimodal interventions directed at both individuals and providers are required to support shared decision-making, goal-directed care, and to overcome barriers to treatment escalation.